Oxantel Pamoate — Competitive Intelligence Brief

Oxantel Pamoate (Oxantel Pamoate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anthelmintic. Area: Infectious Diseases / Parasitology.

marketed Anthelmintic Nicotinic acetylcholine receptors (nematode-specific) Infectious Diseases / Parasitology Small molecule

Target snapshot

Oxantel Pamoate (Oxantel Pamoate) — Swiss Tropical & Public Health Institute. Oxantel pamoate is an anthelmintic that depolarizes and paralyzes nematode muscles, causing expulsion of hookworms and other intestinal roundworms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oxantel Pamoate TARGET	Oxantel Pamoate	Swiss Tropical & Public Health Institute	marketed	Anthelmintic	Nicotinic acetylcholine receptors (nematode-specific)
Egaten	TRICLABENDAZOLE	Novartis	marketed	Anthelmintic [EPC]	Transthyretin	2019-01-01
Albenza	ALBENDAZOLE	Impax Labs Inc	marketed	Anthelmintic [EPC]		1996-01-01
PRAZIQUANTEL	PRAZIQUANTEL		marketed	Anthelmintic [EPC]		1982-01-01
(+/-)-Oxamniquine	OXAMNIQUINE		marketed	Anthelmintic		1980-01-01
Vermox	MEBENDAZOLE		marketed	Anthelmintic [EPC]	Vascular endothelial growth factor receptor 2	1974-01-01
Bovizole	THIABENDAZOLE		marketed	Anthelmintic	Cytochrome P450 1A2	1967-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anthelmintic class)

1. · 2 drugs in this class
2. Swiss Tropical & Public Health Institute · 2 drugs in this class
3. Merck KGaA, Darmstadt, Germany · 1 drug in this class
4. Pfizer · 1 drug in this class